Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Istradefylline - Kyowa Kirin

Drug Profile

Istradefylline - Kyowa Kirin

Alternative Names: KW-6002; NOURIANZ; Nouriast

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Kirin
  • Class Antidepressants; Antiparkinsonians; Neuroprotectants; Small molecules; Xanthines
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • Discontinued Major depressive disorder; Restless legs syndrome; Substance-related disorders

Most Recent Events

  • 14 Oct 2019 Launched for Parkinson's disease (Adjunctive treatment) in USA (PO)
  • 29 Aug 2019 Planned Prescription Drug User Fee Act (PDUFA) date for Parkinson's disease (Adjunctive treatment) in USA (PO) is 2019-08-27
  • 27 Aug 2019 Registered for Parkinson's disease (Adjunctive treatment) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top